Skip to main content
Top
Published in: Malaria Journal 1/2021

Open Access 01-12-2021 | Malaria | Research

Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria in seven countries

Authors: Varunika Ruwanpura, Josselyn Neukom, Koen Peeters Grietens, Ric N. Price, Kamala Thriemer, Caroline A. Lynch

Published in: Malaria Journal | Issue 1/2021

Login to get access

Abstract

Background

The changing global health landscape has highlighted the need for more proactive, efficient and transparent health policy-making. After more than 60 years of limited development, novel tools for vivax malaria are finally available, but need to be integrated into national policies. This paper maps the malaria policy-making processes in seven endemic countries, to identify areas where it can be improved to align with best practices and optimal efficiency.

Methods

Data were collected during a workshop, convened by the Asia Pacific Malaria Elimination Network’s Vivax Working Group in 2019, and subsequent interviews with key stakeholders from Cambodia, Ethiopia, Indonesia, Pakistan, Papua New Guinea (PNG), Sri Lanka and Vietnam. Documentation of policy processes provided by respondents was reviewed. Data analysis was guided by an analytic framework focused on three a priori defined domains: “context,” “actors” and “processes”.

Results

The context of policy-making varied with available funding for malaria, population size, socio-economic status, and governance systems. There was limited documentation of the process itself or terms of reference for involved actors. In all countries, the NMP plays a critical role in initiating and informing policy change, but the involvement of other actors varied considerably. Available evidence was described as a key influencer of policy change; however, the importance of local evidence and the World Health Organization’s endorsement of new treatments and diagnostics varied. The policy process itself and its complexity varied but was mostly semi-siloed from other disease specific policy processes in the wider Ministry of Health. Time taken to change and introduce a new policy guideline previously varied from 3 months to 3 years.

Conclusions

In the medium to long term, a better alignment of anti-malarial policy-making processes with the overall health policy-making would strengthen health governance. In the immediate term, shortening the timelines for policy change will be pivotal to meet proposed malaria elimination milestones.
Literature
2.
go back to reference Pham VH, Gargiulo Isacco C, Nguyen KCD, Le SH, Tran DK, Nguyen QV, et al. Rapid and sensitive diagnostic procedure for multiple detection of pandemic Coronaviridae family members SARS-CoV-2, SARS-CoV, MERS-CoV and HCoV: a translational research and cooperation between the Phan Chau Trinh University in Vietnam and University of Bari “Aldo Moro” in Italy. Eur Rev Med Pharmacol Sci. 2020;24:7173–91.PubMed Pham VH, Gargiulo Isacco C, Nguyen KCD, Le SH, Tran DK, Nguyen QV, et al. Rapid and sensitive diagnostic procedure for multiple detection of pandemic Coronaviridae family members SARS-CoV-2, SARS-CoV, MERS-CoV and HCoV: a translational research and cooperation between the Phan Chau Trinh University in Vietnam and University of Bari “Aldo Moro” in Italy. Eur Rev Med Pharmacol Sci. 2020;24:7173–91.PubMed
3.
go back to reference Kohler JC. I know it when I see it: the challenges of addressing corruption in health systems. Comment on “We need to talk about corruption in health systems”. Int J Health Policy Manag. 2019;8:563–6.PubMedPubMedCentralCrossRef Kohler JC. I know it when I see it: the challenges of addressing corruption in health systems. Comment on “We need to talk about corruption in health systems”. Int J Health Policy Manag. 2019;8:563–6.PubMedPubMedCentralCrossRef
4.
go back to reference Kohler JC, Bowra A. Exploring anti-corruption, transparency, and accountability in the World Health Organization, the United Nations Development Programme, the World Bank Group, and the Global Fund to Fight AIDS, Tuberculosis and Malaria. Global Health. 2020;16:101.PubMedPubMedCentralCrossRef Kohler JC, Bowra A. Exploring anti-corruption, transparency, and accountability in the World Health Organization, the United Nations Development Programme, the World Bank Group, and the Global Fund to Fight AIDS, Tuberculosis and Malaria. Global Health. 2020;16:101.PubMedPubMedCentralCrossRef
5.
go back to reference Walt G, Gilson L. Can frameworks inform knowledge about health policy processes? Reviewing health policy papers on agenda setting and testing them against a specific priority-setting framework. Health Policy Plan. 2014;29(supp_3):iii6–22.PubMedCrossRef Walt G, Gilson L. Can frameworks inform knowledge about health policy processes? Reviewing health policy papers on agenda setting and testing them against a specific priority-setting framework. Health Policy Plan. 2014;29(supp_3):iii6–22.PubMedCrossRef
6.
go back to reference Cairney P. The politics of evidence-based policy making. 1st ed. UK: Palgrave MacMillan; 2016. Cairney P. The politics of evidence-based policy making. 1st ed. UK: Palgrave MacMillan; 2016.
7.
go back to reference Smith K. Beyond evidence-based policy in public health. UK: Palgrave Macmillan; 2013.CrossRef Smith K. Beyond evidence-based policy in public health. UK: Palgrave Macmillan; 2013.CrossRef
8.
go back to reference Parsons W. Public Policy: an introduction to the theory and practice of policy analysis. Aldershot, Brookfield: Edward Elgar; 1995. Parsons W. Public Policy: an introduction to the theory and practice of policy analysis. Aldershot, Brookfield: Edward Elgar; 1995.
9.
go back to reference Williams HA, Durrheim D, Shretta R. The process of changing national malaria treatment policy: lessons from country-level studies. Health Policy Plan. 2004;19:356–70.PubMedCrossRef Williams HA, Durrheim D, Shretta R. The process of changing national malaria treatment policy: lessons from country-level studies. Health Policy Plan. 2004;19:356–70.PubMedCrossRef
10.
go back to reference Durrheim DN, Williams HA, Barnes K, Speare R, Sharp BL. Beyond evidence: a retrospective study of factors influencing a malaria treatment policy change in two South African provinces. Crit Public Health. 2003;13:309–30.CrossRef Durrheim DN, Williams HA, Barnes K, Speare R, Sharp BL. Beyond evidence: a retrospective study of factors influencing a malaria treatment policy change in two South African provinces. Crit Public Health. 2003;13:309–30.CrossRef
11.
go back to reference Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, et al. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J. 2007;6:72.PubMedPubMedCentralCrossRef Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, et al. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J. 2007;6:72.PubMedPubMedCentralCrossRef
14.
go back to reference Adhikari B, Awab GR, von Seidlein L. Rolling out the radical cure for vivax malaria in Asia: a qualitative study among policy makers and stakeholders. Malar J. 2021;20:164.PubMedPubMedCentralCrossRef Adhikari B, Awab GR, von Seidlein L. Rolling out the radical cure for vivax malaria in Asia: a qualitative study among policy makers and stakeholders. Malar J. 2021;20:164.PubMedPubMedCentralCrossRef
15.
17.
go back to reference Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the era of the shrinking P. falciparum map. Trends Parasitol. 2020;36:560–70.PubMedPubMedCentralCrossRef Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the era of the shrinking P. falciparum map. Trends Parasitol. 2020;36:560–70.PubMedPubMedCentralCrossRef
19.
go back to reference Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study. Lancet. 2019;394:332–43.PubMedPubMedCentralCrossRef Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study. Lancet. 2019;394:332–43.PubMedPubMedCentralCrossRef
20.
go back to reference Commons RJ, Simpson JA, Watson J, White NJ, Price RN. Estimating the proportion of Plasmodium vivax recurrences caused by relapse: a systematic review and meta-analysis. Am J Trop Med Hyg. 2020;103:1094–9.PubMedPubMedCentralCrossRef Commons RJ, Simpson JA, Watson J, White NJ, Price RN. Estimating the proportion of Plasmodium vivax recurrences caused by relapse: a systematic review and meta-analysis. Am J Trop Med Hyg. 2020;103:1094–9.PubMedPubMedCentralCrossRef
23.
go back to reference WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
25.
go back to reference Ley B, Luter N, Espino FE, Devine A, Kalnoky M, Lubell Y, et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malar J. 2015;14:377.PubMedPubMedCentralCrossRef Ley B, Luter N, Espino FE, Devine A, Kalnoky M, Lubell Y, et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malar J. 2015;14:377.PubMedPubMedCentralCrossRef
26.
go back to reference Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, et al. Barriers to routine G6PD testing prior to treatment with primaquine. Malar J. 2017;16:329.PubMedPubMedCentralCrossRef Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, et al. Barriers to routine G6PD testing prior to treatment with primaquine. Malar J. 2017;16:329.PubMedPubMedCentralCrossRef
27.
go back to reference WHO. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). Geneva: World Health Organization; 2020. WHO. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). Geneva: World Health Organization; 2020.
29.
go back to reference Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 2017;14:e1002299.PubMedPubMedCentralCrossRef Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 2017;14:e1002299.PubMedPubMedCentralCrossRef
30.
go back to reference Douglas N, Poespoprodjo J, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study. PLoS Med. 2017;14:e1002379.PubMedPubMedCentralCrossRef Douglas N, Poespoprodjo J, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study. PLoS Med. 2017;14:e1002379.PubMedPubMedCentralCrossRef
31.
go back to reference Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Asswariyathipat T, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394:929–38.PubMedPubMedCentralCrossRef Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Asswariyathipat T, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394:929–38.PubMedPubMedCentralCrossRef
32.
go back to reference Llanos-Cuentas A, Lacerda MVG, Hien TT, Vélez ID, Namaik-Larp C, Chu CS, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:229–41.PubMedPubMedCentralCrossRef Llanos-Cuentas A, Lacerda MVG, Hien TT, Vélez ID, Namaik-Larp C, Chu CS, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:229–41.PubMedPubMedCentralCrossRef
33.
go back to reference Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:215–28.PubMedPubMedCentralCrossRef Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:215–28.PubMedPubMedCentralCrossRef
34.
go back to reference Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104:510–20.PubMedPubMedCentralCrossRef Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104:510–20.PubMedPubMedCentralCrossRef
35.
go back to reference Tesfazghi K, Hill J, Jones C, Ranson H, Worrall E. National malaria vector control policy: an analysis of the decision to scale-up larviciding in Nigeria. Health Policy Plan. 2016;31:91–101.PubMedCrossRef Tesfazghi K, Hill J, Jones C, Ranson H, Worrall E. National malaria vector control policy: an analysis of the decision to scale-up larviciding in Nigeria. Health Policy Plan. 2016;31:91–101.PubMedCrossRef
36.
go back to reference Barat LM, Himonga B, Nkunika S, Ettling M, Ruebush TK, Kapelwa W, et al. A systematic approach to the development of a rational malaria treatment policy in Zambia. Trop Med Int Health. 1998;3:535–42.PubMedCrossRef Barat LM, Himonga B, Nkunika S, Ettling M, Ruebush TK, Kapelwa W, et al. A systematic approach to the development of a rational malaria treatment policy in Zambia. Trop Med Int Health. 1998;3:535–42.PubMedCrossRef
37.
go back to reference Shretta R, Omumbo J, Rapuoda B, Snow RW. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health. 2000;5:755–64.PubMedCrossRef Shretta R, Omumbo J, Rapuoda B, Snow RW. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health. 2000;5:755–64.PubMedCrossRef
38.
go back to reference Kamya MR, Bakyaita NN, Talisuna AO, Were WM, Staedke SG. Increasing antimalarial drug resistance in Uganda and revision of the national drug policy. Trop Med Int Health. 2002;7:1031–41.PubMedCrossRef Kamya MR, Bakyaita NN, Talisuna AO, Were WM, Staedke SG. Increasing antimalarial drug resistance in Uganda and revision of the national drug policy. Trop Med Int Health. 2002;7:1031–41.PubMedCrossRef
39.
go back to reference Mubyazi GM, Gonzalez-Block MA. Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug. Malar J. 2005;4:51.PubMedPubMedCentralCrossRef Mubyazi GM, Gonzalez-Block MA. Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug. Malar J. 2005;4:51.PubMedPubMedCentralCrossRef
40.
go back to reference Mulligan J-A, Mandike R, Palmer N, Williams H, Abdulla S, Bloland P, et al. The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania. Trop Med Int Health. 2006;11:452–61.PubMedCrossRef Mulligan J-A, Mandike R, Palmer N, Williams H, Abdulla S, Bloland P, et al. The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania. Trop Med Int Health. 2006;11:452–61.PubMedCrossRef
41.
go back to reference Zikusooka CM, McIntyre D, Barnes KI. Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests? Malar J. 2008;7:176.PubMedPubMedCentralCrossRef Zikusooka CM, McIntyre D, Barnes KI. Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests? Malar J. 2008;7:176.PubMedPubMedCentralCrossRef
42.
43.
go back to reference Kshirsagar N. Malaria: antimalarial resistance and policy ramifications and challenges. J Postgrad Medicine. 2006;52:291–3. Kshirsagar N. Malaria: antimalarial resistance and policy ramifications and challenges. J Postgrad Medicine. 2006;52:291–3.
44.
go back to reference Walt G. Health Policy: an introduction to process and power. Johannesburg: Zed Books; 1994. Walt G. Health Policy: an introduction to process and power. Johannesburg: Zed Books; 1994.
45.
go back to reference VxWG. Targeting vivax malaria in the Asia Pacific: The Asia Pacific Malaria Elimination Network Vivax Working Group. Malar J. 2015;14:484.CrossRef VxWG. Targeting vivax malaria in the Asia Pacific: The Asia Pacific Malaria Elimination Network Vivax Working Group. Malar J. 2015;14:484.CrossRef
46.
go back to reference National Center for Parasitology, Entomology and Malaria Control. Terms of reference of a diagnosis & treatment working group. Cambodia: Ministry of Health; 2020. National Center for Parasitology, Entomology and Malaria Control. Terms of reference of a diagnosis & treatment working group. Cambodia: Ministry of Health; 2020.
47.
go back to reference Ministry of Health. National Strategic Plan for Prevention of Re-introduction of Malaria in Sri Lanka 2018–2022. Sri Lanka: Ministry of Health; 2017. Ministry of Health. National Strategic Plan for Prevention of Re-introduction of Malaria in Sri Lanka 2018–2022. Sri Lanka: Ministry of Health; 2017.
48.
go back to reference Ministry of Health. Decree of the Minister of Health, Republic of Indonesia about Diagnosis and Treatment of Malaria Working Group. Indonesia: Indonesian Ministry of Health; 2017. Ministry of Health. Decree of the Minister of Health, Republic of Indonesia about Diagnosis and Treatment of Malaria Working Group. Indonesia: Indonesian Ministry of Health; 2017.
50.
go back to reference Koduah A, Agyepong IA, Van Dijk H. “The one with the purse makes policy”: power, problem definition, framing and maternal health policies and programmes evolution in national level institutionalised policy making processes in Ghana. Soc Sci Med. 2016;167:79–87.PubMedCrossRef Koduah A, Agyepong IA, Van Dijk H. “The one with the purse makes policy”: power, problem definition, framing and maternal health policies and programmes evolution in national level institutionalised policy making processes in Ghana. Soc Sci Med. 2016;167:79–87.PubMedCrossRef
51.
go back to reference Dodd M, Ivers R, Zwi AB, Rahman A, Jagnoor J. Investigating the process of evidence-informed health policymaking in Bangladesh: a systematic review. Health Policy Plan. 2019;34:469–78.PubMedPubMedCentralCrossRef Dodd M, Ivers R, Zwi AB, Rahman A, Jagnoor J. Investigating the process of evidence-informed health policymaking in Bangladesh: a systematic review. Health Policy Plan. 2019;34:469–78.PubMedPubMedCentralCrossRef
52.
go back to reference Khan MS, Meghani A, Liverani M, Roychowdhury I, Parkhurst J. How do external donors influence national health policy processes? Experiences of domestic policy actors in Cambodia and Pakistan. Health Policy Plan. 2018;33:215–23.PubMedCrossRef Khan MS, Meghani A, Liverani M, Roychowdhury I, Parkhurst J. How do external donors influence national health policy processes? Experiences of domestic policy actors in Cambodia and Pakistan. Health Policy Plan. 2018;33:215–23.PubMedCrossRef
54.
go back to reference Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, et al. Haemolysis in G6PD Heterozygous Females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens. PLoS Med. 2017;14:e1002224.PubMedPubMedCentralCrossRef Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, et al. Haemolysis in G6PD Heterozygous Females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens. PLoS Med. 2017;14:e1002224.PubMedPubMedCentralCrossRef
55.
go back to reference Swanson D, Bhadwal S. Creating adaptive policies: a guide for policymaking in an uncertain world. New Delhi: SAGE Publications Inc.; 2009.CrossRef Swanson D, Bhadwal S. Creating adaptive policies: a guide for policymaking in an uncertain world. New Delhi: SAGE Publications Inc.; 2009.CrossRef
56.
go back to reference Walker WE, Rahman SA, Cave J. Adaptive policies, policy analysis, and policy-making. Eur Oper Res. 2001;128:282–9.CrossRef Walker WE, Rahman SA, Cave J. Adaptive policies, policy analysis, and policy-making. Eur Oper Res. 2001;128:282–9.CrossRef
57.
go back to reference Lancaster K, Rhodes T, Rosengarten M. Making evidence and policy in public health emergencies: lessons from COVID-19 for adaptive evidence-making and intervention. Evid Policy. 2020;16:477–90.CrossRef Lancaster K, Rhodes T, Rosengarten M. Making evidence and policy in public health emergencies: lessons from COVID-19 for adaptive evidence-making and intervention. Evid Policy. 2020;16:477–90.CrossRef
58.
go back to reference Alaerts GJ. Adaptive policy implementation: process and impact of Indonesia’s national irrigation reform 1999–2018. World Develop. 2020;129:104880.CrossRef Alaerts GJ. Adaptive policy implementation: process and impact of Indonesia’s national irrigation reform 1999–2018. World Develop. 2020;129:104880.CrossRef
59.
60.
go back to reference Kumar AM, Satyanarayana S, Wilson NC, Chadha SS, Gupta D, Nair S, et al. Operational research leading to rapid national policy change: tuberculosis-diabetes collaboration in India. Public Health Action. 2014;4:85–8.PubMedPubMedCentralCrossRef Kumar AM, Satyanarayana S, Wilson NC, Chadha SS, Gupta D, Nair S, et al. Operational research leading to rapid national policy change: tuberculosis-diabetes collaboration in India. Public Health Action. 2014;4:85–8.PubMedPubMedCentralCrossRef
61.
go back to reference Chang MC, Baek JH, Park D. Lessons from South Korea Regarding the Early Stage of the COVID-19 Outbreak. Healthcare. 2020;8(3):229.PubMedCentralCrossRef Chang MC, Baek JH, Park D. Lessons from South Korea Regarding the Early Stage of the COVID-19 Outbreak. Healthcare. 2020;8(3):229.PubMedCentralCrossRef
62.
go back to reference Oh J, Lee JK, Schwarz D, Ratcliffe HL, Markuns JF, Hirschhorn LR. National Response to COVID-19 in the Republic of Korea and Lessons Learned for Other Countries. Health Syst Reform. 2020;6:e1753464.PubMedCrossRef Oh J, Lee JK, Schwarz D, Ratcliffe HL, Markuns JF, Hirschhorn LR. National Response to COVID-19 in the Republic of Korea and Lessons Learned for Other Countries. Health Syst Reform. 2020;6:e1753464.PubMedCrossRef
63.
go back to reference Demirbilek Y, Pehlivantürk G, Özgüler Z, Alp Meşe E. COVID-19 outbreak control, example of ministry of health of Turkey. Turk J Med Sci. 2020;50(Si-1):489–94.PubMedPubMedCentralCrossRef Demirbilek Y, Pehlivantürk G, Özgüler Z, Alp Meşe E. COVID-19 outbreak control, example of ministry of health of Turkey. Turk J Med Sci. 2020;50(Si-1):489–94.PubMedPubMedCentralCrossRef
64.
go back to reference Angeli F, Montefusco A. Sensemaking and learning during the Covid-19 pandemic: a complex adaptive systems perspective on policy decision-making. World Develop. 2020;136:105106.CrossRef Angeli F, Montefusco A. Sensemaking and learning during the Covid-19 pandemic: a complex adaptive systems perspective on policy decision-making. World Develop. 2020;136:105106.CrossRef
65.
66.
go back to reference Cherry TL, James AG, Murphy J. The impact of public health messaging and personal experience on the acceptance of mask wearing during the COVID-19 pandemic. J Econ Behav Organ. 2021;187:415–30.PubMedPubMedCentralCrossRef Cherry TL, James AG, Murphy J. The impact of public health messaging and personal experience on the acceptance of mask wearing during the COVID-19 pandemic. J Econ Behav Organ. 2021;187:415–30.PubMedPubMedCentralCrossRef
67.
go back to reference Czypionka T, Greenhalgh T, Bassler D, Bryant MB. Masks and face coverings for the lay public: a narrative update. Ann Intern Med. 2021;174:511–20.PubMedCrossRef Czypionka T, Greenhalgh T, Bassler D, Bryant MB. Masks and face coverings for the lay public: a narrative update. Ann Intern Med. 2021;174:511–20.PubMedCrossRef
68.
go back to reference Bundgaard H, Bundgaard JS, Raaschou-Pedersen DET, von Buchwald C, Todsen T, Norsk JB, et al. Effectiveness of adding a mask recommendation to other public health measures to prevent SARS-CoV-2 infection in Danish mask wearers: a randomized controlled trial. Ann Intern Med. 2021;174:335–43.PubMedCrossRef Bundgaard H, Bundgaard JS, Raaschou-Pedersen DET, von Buchwald C, Todsen T, Norsk JB, et al. Effectiveness of adding a mask recommendation to other public health measures to prevent SARS-CoV-2 infection in Danish mask wearers: a randomized controlled trial. Ann Intern Med. 2021;174:335–43.PubMedCrossRef
69.
go back to reference Sanderson I. Evaluation, policy learning and evidence-based policy making. Public Admin. 2002;80:1–22.CrossRef Sanderson I. Evaluation, policy learning and evidence-based policy making. Public Admin. 2002;80:1–22.CrossRef
70.
go back to reference Sheldrick RC, Hyde J, Leslie LK, Mackie T. The debate over rational decision making in evidence-based medicine: implications for evidence-informed policy. Evid Policy. 2021;17:147–59.CrossRef Sheldrick RC, Hyde J, Leslie LK, Mackie T. The debate over rational decision making in evidence-based medicine: implications for evidence-informed policy. Evid Policy. 2021;17:147–59.CrossRef
71.
go back to reference Foundation BMG. Global health partnerships: assessing country consequences. USA: Bill & Melinda Gates Foundation; 2005. Foundation BMG. Global health partnerships: assessing country consequences. USA: Bill & Melinda Gates Foundation; 2005.
72.
go back to reference Atun R, Bennett S, Duran A. When do vertical (stand-alone) programmes have a place in health systems? Geneva: World Health Organization; 2008. Atun R, Bennett S, Duran A. When do vertical (stand-alone) programmes have a place in health systems? Geneva: World Health Organization; 2008.
73.
go back to reference Oreh A. Effectiveness of vertical versus horizontal programmes: a systematic review of the literature with reference to HIV/AIDS, Malaria and Mental Health, Dissertation, MSc, Tanaka Business School, Imperial College, London, 2007. Oreh A. Effectiveness of vertical versus horizontal programmes: a systematic review of the literature with reference to HIV/AIDS, Malaria and Mental Health, Dissertation, MSc, Tanaka Business School, Imperial College, London, 2007.
74.
go back to reference Cairncross S, Periès H, Cutts F. Vertical health programmes. Lancet. 1997;349:S20–1.CrossRef Cairncross S, Periès H, Cutts F. Vertical health programmes. Lancet. 1997;349:S20–1.CrossRef
75.
go back to reference WHO. World Malaria Report. Geneva: World Health Organization; 2020. WHO. World Malaria Report. Geneva: World Health Organization; 2020.
76.
go back to reference Lane J, Andrews G, Orange E, Brezak A, Tanna G, Lebese L, et al. Strengthening health policy development and management systems in low- and middle- income countries: South Africa’s approach. Health Policy Open. 2020;1:100010.CrossRef Lane J, Andrews G, Orange E, Brezak A, Tanna G, Lebese L, et al. Strengthening health policy development and management systems in low- and middle- income countries: South Africa’s approach. Health Policy Open. 2020;1:100010.CrossRef
77.
go back to reference Mbau R, Gilson L. Influence of organisational culture on the implementation of health sector reforms in low- and middle-income countries: a qualitative interpretive review. Glob Health Action. 2018;11:1462579.PubMedPubMedCentralCrossRef Mbau R, Gilson L. Influence of organisational culture on the implementation of health sector reforms in low- and middle-income countries: a qualitative interpretive review. Glob Health Action. 2018;11:1462579.PubMedPubMedCentralCrossRef
78.
go back to reference Buse K, Mays N, Walt G. Making health policy. Maidenhead, Berkshire: McGraw-Hill Education; 2012. Buse K, Mays N, Walt G. Making health policy. Maidenhead, Berkshire: McGraw-Hill Education; 2012.
83.
Metadata
Title
Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria in seven countries
Authors
Varunika Ruwanpura
Josselyn Neukom
Koen Peeters Grietens
Ric N. Price
Kamala Thriemer
Caroline A. Lynch
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2021
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-021-03959-w

Other articles of this Issue 1/2021

Malaria Journal 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.